Hermetica Superfood Encyclopedia
The Short Answer
Mamala bark contains prostratin (12-deoxyphorbol 13-acetate), a protein kinase C activator that inhibits HIV replication by disrupting viral latency reservoirs at concentrations as low as 1 µM in T-lymphoblastoid and monocytic cell lines. In vitro studies demonstrate that cytoprotective concentrations of prostratin essentially halted HIV-1 reproduction in CEM-SS and C-8166 T-lymphoblastoid cells, human monocytic cell lines, and freshly isolated human monocyte/macrophage cultures, though no human clinical trials have yet confirmed these effects in vivo.
CategoryHerb
GroupPacific Islands
Evidence LevelPreliminary
Primary Keywordmamala Homalanthus nutans benefits
Mamala — botanical close-up
Health Benefits
**Antiviral Activity Against HIV-1**: Prostratin, at concentrations ≥0
1 to >25 µM, protected T-lymphoblastoid cells from HIV-1 cytopathic effects in controlled in vitro studies, suggesting a mechanism relevant to latent viral reservoir clearance.
**Hepatoprotective Traditional Use**
Samoan healers have historically prepared mamala stem bark specifically to treat hepatitis, indicating recognized liver-protective properties within Pacific Island ethnomedicine, though formal hepatoprotective mechanisms remain under-investigated.
**Latent HIV Reservoir Disruption**
Prostratin's PKC-activating properties force latently HIV-infected cells out of dormancy, a strategy being explored in 'shock and kill' therapeutic approaches designed to eliminate viral reservoirs that evade conventional antiretroviral therapy.
**Protein Kinase C Modulation**
By activating PKC isoforms, prostratin initiates downstream signaling cascades affecting immune cell activation, viral gene transcription, and cellular apoptosis pathways, with potential immunomodulatory implications beyond HIV.
**Anti-inflammatory Potential**
Phorbol-related diterpenoids in the Euphorbiaceae family, to which Homalanthus belongs, exhibit modulatory effects on NF-κB signaling, suggesting a plausible anti-inflammatory mechanism that may underlie the traditional hepatitis application.
**Cytoprotection at Low Concentrations**
Notably, prostratin differs from cytotoxic phorbol esters by demonstrating cytoprotective rather than tumor-promoting effects at therapeutic concentrations, a pharmacologically significant distinction that supports its development profile.
Origin & History
Natural habitat
Homalanthus nutans is a tropical tree native to the Pacific Islands, particularly Samoa, Fiji, and other Polynesian island groups, where it grows in lowland and montane rainforest environments. The tree is a fast-growing pioneer species that colonizes disturbed forest edges and secondary growth areas across the South Pacific. In Samoa, distinct populations exist across villages such as Falealupo and Saipipi, with significant genetic and phytochemical variation between populations that influences the concentration of bioactive compounds in harvested tissues.
“Homalanthus nutans holds an established place in Samoan traditional medicine, where it is known as mamala and has been used by indigenous healers (fofō) for generations to treat hepatitis, reflecting sophisticated empirical knowledge of its liver-affecting properties. The plant gained international scientific attention in the 1980s and 1990s through the work of ethnobotanist Paul Alan Cox, who documented its use by Samoan healer Epenesa Mauigoa in Falealupo village, a discovery that subsequently led to the isolation of prostratin and its investigation as an anti-HIV agent. This case became a landmark example of ethnobotanical prospecting leading to pharmaceutical discovery, and it also sparked significant ethical discussions around indigenous intellectual property rights and benefit-sharing agreements between pharmaceutical interests and Pacific Island communities. The village of Falealupo and the Samoan government negotiated benefit-sharing arrangements with the AIDS Research Alliance and related institutions, establishing early precedents for equitable compensation in bioprospecting contexts.”Traditional Medicine
Scientific Research
The evidence base for Homalanthus nutans consists exclusively of preclinical in vitro and phytochemical studies, with no published human clinical trials as of current available literature. Key in vitro work demonstrated that prostratin at cytoprotective concentrations (≥1 µM) halted HIV-1 reproduction in multiple cell line models including CEM-SS, C-8166 T-lymphoblastoid cells, U937 monocytic cells, and primary human monocyte/macrophage cultures. Phytochemical surveys of Samoan populations quantified prostratin content across plant tissues, revealing median concentrations of 3.5 µg/g in stems, 2.9 µg/g in roots, and 2.5 µg/g in leaves, with extreme inter-population variability ranging from 0.20 to 52.69 µg/g — a more than 100-fold range that complicates standardization. The overall evidence quality is classified as preliminary-preclinical; while mechanistic rationale is scientifically credible and prostratin is under active pharmaceutical investigation, no randomized controlled trials or systematic human efficacy data exist to support clinical recommendations.
Preparation & Dosage
Traditional preparation
**Traditional Samoan Preparation**
Inner bark and stem tissue are prepared as decoctions by Samoan healers (fofō) for oral administration in hepatitis treatment; specific volumes and preparation ratios are not standardized in published literature.
**Pharmaceutical Research Form**
Purified prostratin isolated from stem tissue is used in laboratory settings at concentrations of 0.1–25 µM for in vitro antiviral studies; no commercial supplement form exists.
**Tissue Selection**
Stem bark yields the highest median prostratin concentration (3.5 µg/g) and is the tissue historically preferred by traditional healers, consistent with ethnobotanical recommendations.
**Standardization Status**
No standardized commercial extract with defined prostratin percentage is currently available; the extreme variability in prostratin content (0.20–52.69 µg/g across populations) makes standardization challenging.
**Clinical Dose**
No human-equivalent therapeutic dose has been established; all dosing information pertains to in vitro cell culture models and cannot be directly extrapolated to human supplementation.
Nutritional Profile
Homalanthus nutans is not used as a food ingredient and has no meaningful macronutrient or micronutrient profile relevant to nutritional supplementation. The pharmacologically relevant phytochemical is prostratin (12-deoxyphorbol 13-acetate), a tigliane diterpene ester present at median concentrations of 2.5–3.5 µg/g in various plant tissues, with exceptional variability (0.20–52.69 µg/g) depending on population origin and tissue type. Other phorbol-type diterpenoids and terpene constituents likely co-occur in the bark matrix, as is characteristic of the Euphorbiaceae family, but these have not been systematically characterized for mamala specifically. Bioavailability of prostratin from crude plant preparations in humans is entirely unknown, as no pharmacokinetic studies have been conducted.
How It Works
Mechanism of Action
Prostratin (12-deoxyphorbol 13-acetate) is a tigliane-type diterpene ester that binds to the C1 domain of protein kinase C (PKC) isoforms, functioning as a PKC activator without the tumor-promoting activity associated with classical phorbol esters such as TPA. This PKC activation upregulates NF-κB-dependent transcription of HIV-1 proviral DNA integrated within latently infected CD4+ T-cells and monocytes, driving latent virus into active replication where it becomes susceptible to immune clearance and antiretroviral suppression. At the cellular level, prostratin concurrently downregulates surface expression of CD4 and CXCR4, the primary receptor and co-receptor through which HIV-1 enters host cells, thereby reducing new infection events even as latent reservoirs are being purged. This dual action — proviral activation combined with receptor downregulation — underpins its mechanistic rationale as an adjuvant to standard antiretroviral therapy in functional HIV cure strategies.
Clinical Evidence
No completed human clinical trials investigating mamala extract or isolated prostratin for any clinical indication have been identified in the available literature. The entirety of formal research has been conducted in cell culture models and phytochemical characterization studies, which, while mechanistically informative, cannot establish human efficacy, optimal dosing, or safety profiles. Prostratin's role in HIV latency reversal has attracted significant pharmaceutical interest, and it has been evaluated as a candidate for inclusion in 'shock and kill' HIV cure protocols, but these investigations remain in preclinical and early translational phases. Confidence in clinical outcomes is correspondingly very low, and any therapeutic use in humans is not supported by current evidence-based standards.
Safety & Interactions
The safety profile of mamala bark preparations and isolated prostratin in humans is essentially uncharacterized, as no formal clinical safety studies, dose-escalation trials, or post-marketing surveillance data exist. Prostratin belongs to the phorbol ester chemical class, members of which are known to act as tumor promoters at high doses through sustained PKC activation; however, prostratin is specifically noted to lack tumor-promoting activity at the concentrations investigated in vitro, and its long-term safety implications at pharmacological doses in humans remain untested. Potential drug interactions with antiretroviral medications, immunosuppressants, or other PKC-modulating agents are plausible based on its mechanism of action but have not been studied. Use during pregnancy and lactation is contraindicated by precaution given the complete absence of safety data, and self-administration of crude bark preparations outside of supervised ethnomedicinal contexts is inadvisable.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Homalanthus nutansMamala treeOlopua (Samoa)bleeding heart treeprostratin plant source
Frequently Asked Questions
What is mamala used for in traditional medicine?
In Samoan traditional medicine, mamala (Homalanthus nutans) stem bark is prepared by indigenous healers (fofō) as a decoction used to treat hepatitis. The plant's liver-protective application represents generational empirical knowledge, and it was documentation of this use by ethnobotanist Paul Alan Cox that led researchers to investigate its bioactive compound prostratin for antiviral properties.
What is prostratin and how does it work against HIV?
Prostratin (12-deoxyphorbol 13-acetate) is a tigliane diterpene ester found in mamala bark that activates protein kinase C (PKC) isoforms, forcing latently HIV-infected CD4+ T-cells and monocytes to begin active viral replication. Simultaneously, prostratin downregulates CD4 and CXCR4 surface receptors, reducing new infection events — a dual mechanism that makes it a candidate adjuvant to antiretroviral therapy in HIV cure strategies, though only in vitro evidence currently exists.
Has mamala or prostratin been tested in human clinical trials?
No completed human clinical trials for mamala extract or purified prostratin have been published as of available literature. All formal efficacy data comes from in vitro cell culture studies demonstrating HIV inhibition in T-lymphoblastoid cells, monocytic cell lines, and primary human macrophages. Prostratin remains in preclinical and early translational research phases, and clinical dosing or efficacy in humans cannot be confirmed.
How much prostratin is in mamala bark?
Prostratin concentrations in Homalanthus nutans vary dramatically depending on the plant population and tissue type. Stem bark has a median concentration of approximately 3.5 µg/g, roots contain about 2.9 µg/g, and leaves around 2.5 µg/g. However, individual plant samples from Samoan populations range from as little as 0.20 µg/g to as high as 52.69 µg/g — a more than 100-fold difference — making standardization of any extract extremely challenging.
Is mamala bark safe to take as a supplement?
The safety of mamala bark as a human supplement is entirely unestablished, as no clinical safety studies, pharmacokinetic data, or toxicology trials in humans have been conducted. Prostratin belongs to the phorbol ester chemical class, which at high doses is associated with tumor promotion through sustained PKC activation, though prostratin itself lacks this activity at in vitro therapeutic concentrations. Until human safety data are available, self-administration of mamala preparations is not recommended, and use during pregnancy or lactation should be avoided as a precaution.
Does mamala interact with antiretroviral HIV medications?
While prostratin from mamala shows promise for HIV latent reservoir clearance, there is limited clinical data on interactions with current antiretroviral drugs like integrase inhibitors or protease inhibitors. Anyone taking HIV medications should consult their healthcare provider before adding mamala supplements, as prostratin's mechanism of activating latent HIV could potentially interfere with standard treatment regimens. In vitro studies cannot predict real-world drug interaction risks in patients on combination therapy.
Is mamala safe to use if I have liver disease or hepatitis?
Although Samoan traditional medicine has used mamala bark to treat hepatitis, there are no modern clinical trials confirming its safety or efficacy in people with active liver disease. Patients with hepatitis or compromised liver function should avoid self-treating with mamala and instead work with their healthcare provider, as liver conditions require monitored medical care. The historical use does not guarantee safety for individuals with diagnosed hepatic conditions.
How does the bioavailability of prostratin differ between mamala bark extract and whole bark powder?
Prostratin concentration varies significantly depending on extraction method, with some studies using purified compounds at concentrations (0.1–25 µM) that differ substantially from what whole bark powder would naturally deliver. Standardized bark extracts designed to concentrate prostratin may provide more consistent dosing than raw powder, but absorption rates in the human body have not been formally compared between these forms. The optimal formulation for systemic bioavailability remains unclear due to limited human pharmacokinetic data.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w mamala-homalanthus-nutans curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
